Abstract:
Introduction

2
G protein-coupled receptors (GPCRs), the largest family of cell-surface receptors (>800 in the human genome), 3 mediate the signaling of a wide variety of ligands, including hormones, neurotransmitters, proteases, lipids, and 4 peptides. GPCRs regulate many functions (e.g., metabolism, migration, proliferation) and interactions of cells with 5 their environment. GPCRs are also the largest family of targets for approved drugs [3, 4] , interacting with ~35% of 6 FDA approved drugs, but are infrequently targeted in tumors other than endocrine cancers, even though a role for
7
GPCRs has been implicated in features of the malignant phenotype [5, 6] . One reason for their limited use is the 8 notion that GPCRs are rarely mutated in cancer [7, 8] although mutations occur in heterotrimeric GTP binding (G)
9
proteins that GPCRs activate [8] and GPCRs regulate pathways, such as Wnt, MAPK and PI3K signaling, with 10 mutations in cancer [9] . The biological relevance of GPCRs for the malignant phenotype and their high 11 druggability imply that GPCRs might be an under-explored class of contributors to and targets in cancer.
13
To define the landscape of GPCRs in cancer, we undertook an integrated analysis of Differential Expression (DE), 
16
normal tissue, respectively, an analysis facilitated by the TOIL recompute project [10] . We studied GPCRs 17 annotated by GtoPdb [2] , including endoGPCRs (which respond to endogenous agonists) and taste receptors but 
15
(E-F) For two highly expressed GPCRs in (A-D) as examples, the median expression of (E) GPRC5A and (F)
16
GPR143 in all tumor types tested and corresponding normal tissue, normalized in CPM, allowing for comparison 
2
Differential expression (DE) of GPCRs in solid tumors compared to normal tissues 3 4 We focused on GPCRs with both substantial DE and magnitude of expression in solid tumors, i.e., 1) > 2-fold 5 increase/decrease in DE in tumors compared to normal tissue, 2) FDR < 0.05 and 3) median expression in tumors 6 > 1 TPM. We used the latter threshold for median expression in order to identify GPCRs that may be useful as 7 therapeutic targets, for which higher expression is preferable. For DE analysis, we divided the 20 TCGA tumor 8 types into 45 tumor subtypes (Table 1) , based on histological classification of tumors in TCGA metadata. We 9 found that different tumor subtypes within the same TCGA tumor classification have distinct GPCR expression, 10 e.g., subtypes of breast cancer (BRCA), thyroid cancer (THCA) and esophageal cancer (ESCA) (Figs S1A-F).
12
Figure 1A shows a heatmap with fold changes (where statistically significant) for mRNA expression of all GPCR Figure 1D shows the same, but for GPCRs frequently reduced >2-fold in 23 expression, but which are still detected at >1 TPM in those tumors. Among the GPCRs with frequently increased 24 expression are receptors likely expressed in the tumor cells themselves (e.g., GPRC5A, [11, 12] ) and expressed in 25 the tumor microenvironment, such as in fibroblasts (e.g., F2R, [13] ) and immune cells (e.g., FPR3, CCR1, CCR5). 
27
36
Many GPCRs show DE in tumors, including those from each GPCR class: A (rhodopsin-like), B (secretin-like), C
37
(metabotropic glutamate and others), frizzled and adhesion GPCRs. The highest expressed GPCRs in PDAC 38 tumors (as an example, this finding is generalizable to other tumor types) are generally overexpressed compared 39 to normal tissue and include orphan receptors (e.g., GPRC5A and ADGRF4/GPR115) and GPCRs with known 40 agonists (e.g., GPR68) (Fig 2A, C) . GPRC5A, the most highly expressed GPCR in PDAC, is 50-fold higher 41 expressed; 95% of PDAC samples have >8-fold higher median GPRC5A expression than in normal pancreas (Fig   42   S3I ). Within a tumor type, a large majority of individual tumors express such overexpressed GPCRs at far higher 43 levels than corresponding normal tissue (Fig 3A, e.g., GPRC5A); a subset of GPCRs are expressed in >90% of
44
PDAC tumors at abundances greater than in any normal pancreas sample (Fig 2F) . As discussed in subsequent couple to all major classes of Gα G protein signaling mechanisms (Fig 3C) . 49 50 1 skin cutaneous melanoma (SKCM) (Fig 2B, D) ; ADGRG1/GPR56, GPR143 and EDNRB are highly 2 overexpressed and highly expressed in magnitude compared to normal skin in >90% of melanoma samples ( Figs   3 
S3G-I).
In general, such highly overexpressed GPCRs are expressed in the vast majority, typically >90%, of 4 samples within a tumor subtype. Figure 2E shows the median expression of GPRC5A, the highest expressed GPCR in PDAC (and highly 
6
13
GPCRs tends to be more prevalent within specific tumor types/subtypes than are common mutations. For 14 example, KRAS and TP53 are the most frequently mutated genes in PDAC (>70% and >60% of TCGA samples,
15
respectively) but increased expression of multiple GPCRs occurs with greater frequency (Fig 3B) . Each GPCR
16
shown in Figure 3B shows statistically elevated expression in tumors compared to normal tissue, with FDRs << 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32 33 34 
11
ADORA2B, CCR5 and F2R, which are overexpressed in 27, 27 and 26 tumor subtypes, respectively. Table S4   12 and Supplement 3 provide further details regarding such druggable GPCRs.
14
Data generated and mined in this study, including DE analysis, re-normalized GPCR expression data, expression 15 of every GPCR in every individual tumor sample analyzed, accompanying CNV data and mutation data for 
24
Patterns of GPCR expression across solid tumors 25 26 Figure 4A shows a heatmap that plots median GPCR expression in TPM across all tumor types, for all non-
27
olfactory GPCRs and reveals that GPCRs can be divided into four groups: a) those widely expressed at high 
34
We also performed hierarchical clustering on tumor types to explore whether GPCR expression is distinct in 
46
GPCR expression is associated with cancer-related pathways and with survival: PDAC as an example 47 
48
A subset of GPCRs in PDAC is highly overexpressed and prominently expressed in tumors and in PDAC cells correlates with a subset of ~1200 genes (Benjamini-Hochberg adjusted p-values < 0.001) (Fig S5A) . A 1 reconstruction of the resulting network of genes using STRING [14] is shown in Figure 6A .
3
We conducted further analyses related to PDAC, including with GSEA [15] of the sets of negatively and positively 4 associated genes (with respect to the five gene marker described above), pre-ranked/weighted by their FDRs and
5
found an enrichment of a number of KEGG [16] pathways relevant to cancer (Fig 6B) . The set of positively 6 associated genes shows similar associations with cancer-related pathways when analyzed via GO [17, 18] [19] . Enrichr also identifies, based on the Jensen compartment database [20] , an enrichment of vesicle 8 and exosome-related gene products among the set of positively correlated genes (Fig 6C) . Network-analysis of 9 the genes positively associated with the composite GPCR marker via STRING [14] provides an intuitive picture of 10 this gene set (Fig 6A) . Two 'clusters' of genes and pathways are evident; those associated with KRAS (including
11
KRAS itself) and related processes (e.g., focal adhesion pathways) and a second group associated with 12 regulation of cell cycle, cell division and differentiation. Expression of highly overexpressed GPCRs is positively 13 correlated with one another and with expression of KRAS, implicating this GPCR subset as a PDAC signature.
14 Leading edge analysis of the GSEA results confirmed that KRAS and other oncogenes are common elements in 15 multiple enriched gene sets associated with this GPCR signature (Fig 6D) . Survival analysis indicates that GPCR 16 expression has prognostic relevance: patients with above-median expression of the five GPCRs had a ~200-day
17
shorter survival compared to those with less than the median expression (Fig 6F; Fig S3A) .
19
We tested whether we could identify associations between GPCR expression in PDAC tumors and expression of 20 markers for cell types commonly found in these tumors, thereby perhaps serving as an indicator for the cell types 
29
consistent with evidence that it is a novel functional receptor in PDAC-derived CAFs [13] . Similarly, epithelial-
30
enriched GPCRs ( Figure 6E ) are expressed in cancer cells [21] and as shown below, in cancer cell lines.
32
PDAC tumors have a subset of highly overexpressed (and highly expressed in terms of magnitude) chemokine immune-associated processes, especially T-cell and B-cell related pathways (Fig S4B) . Combined expression of 36 these GPCRs is a positive predictor of survival (Fig 6G) . The observation that GPCR expression may be a marker 37 for survival is not unique to PDAC (Fig 9D-F 
41
The finding that GPCRs with high expression and DE in tumors show an association with tumorigenic pathways 
49
( Figs S5 A-C) , such as transferrin transport [22] , melanosome organization [23] and insulin receptor signaling [24] . In general, highly expressed GPCRs in solid tumors show a positive correlation between GPCR expression 1 and expression of tumorigenic pathways, implicating these GPCRs as potentially "functional oncogenes".
3
Functionality of overexpressed GPCRs 
5
Evidence for functional roles in cancer cells of GPCRs that are highly expressed and overexpressed in solid 6 tumors and cancer cells include findings for PAR1/F2R in breast cancer [25] , gastric cancer [26] , colon cancer 7 [27] and melanoma [28] cells and for PAR2/F2RL1 in melanoma [28] , breast [29] and colon cancer cells [30] .
8
Higher PAR2 expression in ovarian cancer predicts poorer prognosis [31] . EDNRB, which is highly overexpressed 9 in SKCM, promotes migration and transformation of melanocytes and melanoma cells and inhibition of EDNRB is 10 pro-apoptotic [32, 33] . GPR143 promotes migration [34] and chemotherapeutic resistance [35] of melanoma cells.
11
GPR160 and GPRC5A, two frequently overexpressed GPCRs, are orphan receptors that influence the malignant 12 phenotype. Knockdown of GPR160 in prostate cancer cells increases apoptosis and growth arrest [36] . It has 13 been suggested that GPRC5A is an oncogene that promotes proliferation, migration and colony formation of 14 PDAC cells [11, 12] . GPCRs with increased expression may thus be functional in cancer cells and activated by 15 endogenous agonists or have constitutive activity that regulates signaling via heterotrimeric G proteins and/or β-
16
arrestin [4] . At least certain of the many overexpressed GPCRs may thus serve as phenotypic drivers.
18
Incorporating omics analysis similar to what is presented here, our laboratory has recently shown [13] that GPR68
19
(a proton-sensing GPCR) is highly overexpressed in PDAC tumors, in particular, in CAFs. We validated these 20 data at the protein level and discovered that GPR68 mediates symbiotic crosstalk between CAFs and PDAC cells 
25
Driver mutations, patient sex and stage/grade of tumors does not impact on GPCR expression 26 27 GPCR expression and DE is largely independent of tumor stage and grade. Figure 3D shows the similarity in
28
GPCR expression for Grades 1 to 3 (G1 to G3) PDAC tumors. Median expression of GPCRs was also similar in
29
PDAC tumors with different pathological T (Fig 3E) . Similarly, Stage I and Stage IIIA BRCA IDC HR+ (Hormone
30
Receptor positive) tumors have comparable GPCR expression and DE (Fig 7D) . 31 
32
GPCR expression appears largely independent of driver mutations, such as in BRCA HR+ IDC tumors with either
33
PI3KA or P53 mutations (Fig 7A-C) ; both groups have similar GPCR expression and DE of the same GPCRs 34 compared to normal breast tissue. Similar results occur for LUAD and STAD that have or lack P53 mutations.
35
Increased GPCR expression in solid tumors may thus not depend on specific driver mutations. Presence of highly
36
overexpressed GPCRs may be a more ubiquitous feature of tumors than the presence of specific driver 37 mutations, as exemplified by PDAC (Fig 3B) and in other tumor types with DE of numerous GPCRs ( Table 1) .
39
Moreover, GPCR expression also appears to be independent of a patient's sex. 
10
GPCRs highly expressed in tumors are highly expressed in cancer cells 11 12 We assessed RNA-seq data for GPCR expression in cancer cell lines from the EBI portal generated via the iRAP 13 analysis pipeline [37] for cell lines in CCLE [38] and from Genentech [39] . The use of a different analysis pipeline 14 than that used for TCGA data does not allow direct statistical comparisons of the datasets but confirms that most
15
GPCRs in TCGA tumors are present in cancer cells and vice versa. We also mined RNA-seq for primary 16 melanoma cells [40] and PDAC cells [41] from the NCBI GEO database. The data from these sources (Methods,
17
Section 1) allow an approximate comparison with data for tumors. Supplement 3 shows GPCR expression in 18 cancer cell lines.
20
As an example, GPCRs with the highest median expression in TCGA PDAC tumors are generally highly 21 expressed in PAAD (pancreatic adenocarcinoma, most likely PDAC) cell lines and patient-derived PDAC cells 22 [41] (Fig 7G) . A few exceptions exist, perhaps from effects of cell culture or expression by non-cancer cells in 23 tumors. Even so, highly expressed GPCRs in PAAD cells are highly expressed in PDAC tumors (Fig 7H) , findings 24 that also occur in other tumors, such as SKCM (Fig 7I, J) . Thus, most highly expressed GPCRs in tumors are 25 also highly expressed in cancer cells and vice versa.
27
Most overexpressed GPCRs are rarely mutated 28 
29
The most frequently mutated GPCRs in solid tumors are rarely overexpressed (Figs 8A-B, 10H) and conversely,
30
highly overexpressed GPCRs in solid tumors are rarely mutated (Fig 8A-B, Supplementary Table 5 ). In SKCM,
31
which has the highest mutation burden among TCGA tumor types, the most highly overexpressed GPCRs
32
(GPR143, EDNRB and GPR56) are mutated in <2% of SKCM tumors whereas frequently mutated GPCRs (e.g.,
33
GPR98, mutated in nearly 40% of tumors) typically have low expression. The most frequently overexpressed
34
GPCRs across all tumors (e.g., FPR3; Table S5 ) are mutated in <1% of all tumors surveyed, compared to 35 frequently mutated GPCRs, e.g., GPR98, GPR112, which are mutated in >5% of all TCGA tumors surveyed.
36
Thus, the frequency of GPCR mutations and likelihood of overexpression do not correlate (Fig 8B) . The majority 
5
(B) KEGG [16] gene sets with positive enrichment among genes most significantly positively or negatively 6 correlated with expression of the identified subset of overexpressed GPCRs, based on GSEA pre-ranked analysis 7
[15]. 8 (C) Enrichr [19] analysis of the genes positively correlated in (A), with FDR < 0.001, based on their enrichment in 9 cellular compartments, from the Jensen compartment database [20] . 10 
12
(G) Median expression of highest expressed GPCRs in PDAC tumors compared to cancer cells (CCLE [38] , n = 13 33; Genentech [39] , n = 16; Witkiewicz et al., [41] , n = 72). The predicted association of expressed GPCRs with Gα G proteins 1 2 Supplement 2 shows GPCRs annotated in the IUPHAR / BPS Guide to Pharmacology GPCR database [2] , their 3 signal transduction via G protein heterotrimers and if they are orphan GPCRs. Tissues and tumors typically 4 express >150 GPCRs (at detection thresholds >0.1 TPM) that couple to the major types of G proteins (Gs, Gi/o,
5
Gq/11, G12/13), most frequently Gi/Go and Gq/G11 (Figs S6A-B) . We calculated the abundance of GPCRs that 6 couple to each G protein by summing median GPCR expression (TPM), thereby yielding an expression 7 'repertoire' for each signaling mechanism (Figs S6C-D) . Gs-coupled GPCRs typically account for the smallest 8 GPCR expression repertoire for which such coupling is known. Supplement 3 provides GPCR expression and G 9 protein linkage data for normal tissues and solid tumors. Summing expression (TPM) of all GPCRs provides an 10 estimate of the proportion of GPCRs among total mRNA (Figs S6E-F) .
12
The GPCR expression repertoire varies among tissues in terms of total expression, number and identities of 13 GPCRs. Tumors typically have a different GPCR repertoire than normal tissue, with increased or decreased 14 expression of many GPCRs (Fig 1C, Figs S6E-F) . Total GPCR expression and the number of GPCRs above 15 expression thresholds increases in certain tumors (e.g., PDAC) but decreases in others (e.g., LIHC and SKCM) 16 compared to normal tissue. Tumors also differ from normal tissue with respect to the abundance of GPCRs that 17 couple to different G proteins (Fig 1I, Figs S6C-D) , suggesting changes in signaling. For example, Gs-coupled
18
GPCR expression decreases in many tumors (e.g., PDAC, Fig 3C) , implying decreases in cAMP signaling.
20
GPCRs as potential therapeutic targets in cancer 21 22 Among the >200 GPCRs overexpressed in at least one of the 45 tumor subtypes, 77 are targets for drugs 
27
thirds link to either Gs-or Gi-coupled signaling and thus are predicted to regulate cAMP formation (Fig 9B) . 28 
29
Of the solid tumor types we analyzed, lung, colon, pancreatic, breast, and prostate cancers account for the largest 
38
As a protein-coding family of genes, GPCRs are disproportionately enriched among overexpressed genes in solid 39 tumors, when compared to all protein-coding genes. Evidence for this was obtained as follows: In each tumor type 40 indicated (Fig 9G-H) , the ratio of number of coding genes with increased expression (above a prescribed 
47
Moreover, extending from the data shown in fig (6F-G) , we find that many GPCRs expressed by solid tumors may 48 be prognostic markers. GPCR mRNA expression is associated with differences in survival in multiple tumor types 49 (Fig 10) . Using GPCR expression normalized in CPM, we performed survival analysis using the modified Peto-
50
Peto test for every GPCR in tumor types where sufficient numbers of TCGA replicates were available (typically 51 (Fig 10D) .
12
For two tumor types as examples (ESCA Adenocarcinoma and SKCM distant metastases, Fig 10E-F) , we show 13 the difference in mean survival times (in days) between patients with high expression (above median) and low 14 expression (below median); negative values imply that elevated expression of these GPCRs is associated with 15 adverse survival rates. GPCR expression is associated with both negative and positive survival effects,
16
depending on the tumor type and GPCR. Several GPCRs are associated with differences in survival of >1 year.
17
Some GPCRs have low median expression (<1 TPM) in the tumor population in general (e.g., taste receptors
18
TAS2R14 and TAS2R20 in ESCA) but may be expressed in subsets of these populations, wherein they may 19 contribute to differences in survival. Our analysis focusses on higher expressed GPCRs but we provide (at the 
23
In total, we found that 301 GPCRs show statistically significant evidence (p <0.05) of an association with survival, 10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 58 59 (Fig 11A, S8A) , including a more frequently mutated subset (Fig 11A, inset) . GPR98/ADGRV1, the 5 most frequently mutated GPCR, occurs in >8% of TCGA samples. Tumor types with high mutation burdens have 6 a high frequency of GPCR mutations (Fig 11B) . SKCM has the highest frequency: ~40% SKCM tumors have 7 GPR98 mutations (Fig 11C, H) . Approximately 65% of tumors have ≥1 non-silent GPCR mutation. Certain
8
GPCRs are mutated in >10% of specific tumor types (Fig 11C) .
10
Nmut, the number of genes with somatic non-silent mutations per tumor genome, and the number of mutated
11
GPCRs scale linearly in individual tumors (Figs 11D, S8E-G) . Frequently mutated GPCRs (e.g., GPR98,
12
GPR112, and BAI3) are more likely to be mutated as Nmut increases (Fig 11E, SKCM as an example) . The 13 relationship between Nmut and likelihood of GPR98 mutation is similar in SKCM and other cancers (Fig 11F) ; this 14 is also observed for other frequently mutated GPCRs. Hence, the likelihood of a GPCR being mutated appears to 
20
Missense mutations and in-frame deletions are the most frequent non-silent mutations in GPCR genes (Fig S8C- 
21
D, Table S3 ). Mutations in frequently mutated GPCRs occur at many sites (Fig S9A) , which contrasts with the
22
smaller number of such sites in common oncogenes, e.g., KRAS [9] . (Fig S9B) . Certain GPCR genes (e.g., 23
GPR98) may be in genomic regions vulnerable to dysregulation of DNA damage and repair and belong to a 24 subset of mutated genes; GPR98 mutations frequently occur alongside other frequently mutated genes such as
25
TTN and MUC16 (Fig S10A-G) . GPR98 is among the 25 most frequently mutated genes in all tumor types 26 surveyed; its mutational frequency is similar to that of genes (e.g., BAGE2 [Fig S8B] ) that are mutational hotspots 27 [42] . As the GPCR with the largest gene length (~19,000 bp), GPR98 has more mutational events. Compared 28 with other very long genes, e.g., genes > 10,000 bp, GPR98 belongs to a subset of ~20 genes with high 29 mutational frequencies (Fig 12A) , implicating GPR98 as a hotspot for both silent and non-silent somatic 30 mutations. GPR98 has a >4-fold increased density of mutational events (normalized for gene length) compared to 31 the average of these very long genes. One obtains a similar result by assessing the density of somatic mutations 32 across all genes, irrespective of length (Fig 12B) . GPR98, GPR112 and BAI3 are among the top 5% of genes in 33 number of mutations per unit gene length, highlighting these genes as chromosomal regions with higher than 34 normal rates of somatic mutation.
36
Survival analysis of metastatic SKCM samples was performed in order to evaluate the impact on tumors of 37 somatic non-silent mutations to GPR98, GPR112, or other frequently mutated GPCRs. Analysis of Kaplan-Meier 38 survival curves using the modified Peto-Peto method reveals that presence of somatic mutations in these GPCRs
39
does not have a statistically significant impact on survival. Fig 12C-D shows this for GPR98 and GPR112, the two 40 most frequently mutated GPCRs in SKCM. We find the same result in other tumor types as well and thus
41
conclude that somatic non-silent mutations to GPCRs have no impact on patient survival.
43
Most mutated GPCR genes have low levels of mRNA expression (Fig 8; 11G 
49
GPCR mutations (e.g., GPR98 and LPHN2) revealed little evidence that these mutations alter the tumor 50 transcriptome, implying that such GPCR mutations are likely passenger, rather than driver, mutations (Fig 11H; Fig S8C, D) . Conversely, previous work has suggested that for known oncogenes (e.g., for TP53, [43] ), there are 1 often widespread transcriptomic changes associated with specific mutations. We found similar behavior for other 2 tumors (e.g., BLCA) that have frequent GPCR mutations.
4
As a further approach, we evaluated GPCR mutations, predicting the likelihood of functional consequences and 5 site-specific enrichment of the mutations via MutSig 2CV v3.1 (gdac.broadinstitute.org). The majority of GPCRs 6 frequently mutated (Fig 11-I, SKCM as example) show non-silent mutations that are non-significant in terms of 7 enrichment (compared to the background mutation rate of silent mutations over the same regions) for individual 8 mutation sites. These mutations are not predicted to be functional (calculated from estimations of functional 9 impact of mutations based on whether mutated regions are highly evolutionarily conserved) by MutSig 2CV, 10 consistent with the idea that the frequent GPCR mutations are likely passenger and not driver mutations. MutSig 
11
2CV results for all GPCRs in all tumor types are available at the accompanying website. 
7
(D) GPCR mutation frequency is linearly related to Nmut in SKCM.
8
(E) Probability of GPCR mutation as Nmut increases in SKCM for the 10 most frequently mutated GPCRs 9 (F) Normalized probability of GPR98 mutation as Nmut increases in SKCM, and the same for several cancers 10 with high mutational burden and combined for BLCA, LUAD, LSQC, COAD, and SKCM. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 Copy-number variation (CNV) of GPCRs in solid tumors 1 2 CNV of certain GPCRs occurs frequently in TCGA solid tumor samples (Fig 13A-B GPCRs (e.g., GPR160) amplified in >5% of all TCGA samples surveyed. CNV data were obtained as GISTIC 2.0 4 [44] thresholded data, wherein values of -2, -1, 0, 1 and 2 respectively denote homozygous deletion, single copy 5 deletion, diploid copy number, low level amplification (i.e. increase of 0.1 to 0.9 of copy number, expressed as a 6 log2 ratio) and high-level amplification (amplification of >0.9 of the log2 ratio, i.e. >1.7 extra copies in a diploid 7 cell) [45] . The distribution of amplification events among GPCRs parallels that of all genes (Fig 13C, SKCM as an   8 example) but a subset of GPCRs is disproportionally amplified (Fig 13D-F, and Supplement 3) . Most GPCRs 9 have infrequent amplification (in 2% of tumors or less). Amplification does not predict high expression or 10 overexpression of GPCRs (Fig 13G-J; OV as an example): frequently amplified GPCRs in tumors often have 11 limited mRNA expression in those tumors while most highly expressed, overexpressed GPCRs are not amplified.
13
Single-copy/heterozygous deletions of GPCRs are widespread, whereas homozygous deletions are rare (Fig   14   13A, D) . GPCR genes with single-copy deletions are generally not significantly expressed in tumors or normal Figure 13E shows the identity/frequency of amplification of the most frequently amplified GPCR in each tumor 21 type. Several cancers (e.g., OV and LSQC) have a high level of amplification of specific GPCRs in >25% and low-22 level amplification in >40% of samples. Figure 13F shows the CNA frequency of GPR160, the most frequently Fig 13H) 
20
30
of expressing GPR160 at levels above the median for OV. We did not observe statistically significant risk ratios 31 relating GPCR expression with amplification for other frequently amplified GPCRs. We conclude that CNA and 32 GPCR mRNA expression are generally poorly correlated; hence, examination of amplified GPCR genes does not 33 predict which GPCRs are highly and/or differentially expressed in a tumor (Fig 13I, J) .
35
Supplements 2 and 3 provide, respectively, the frequency of GPCR CNV and changes in expression of GPCRs 36 in the tumors surveyed. The widespread CNV of certain GPCRs suggests that they (and/or neighboring genes 37 that vary along with these GPCRs) contribute to the malignant phenotype and may be markers for malignancy.
39
Discussion and Conclusions
2
In this study, we identified mutations, CNVs and alterations in mRNA expression of GPCRs in a range of solid 
6
Mutations of certain GPCRs have been implicated in cancer [8] , but a comprehensive analysis of GPCR 
13
Our analysis identified frequently mutated GPCRs (e.g., GPR98/ADGRV1 and GPR112/ADGRG4) in multiple 
5.
The lack of effect of GPCR mutations on gene expression
28
While GPCRs are of interest in cancer due to their high mRNA expression, using their frequency of mutation as a
29
rationale to choose particular GPCRs as potentially functionally important or possible therapeutic targets is likely a
30
flawed approach-a conclusion that contrasts with previous suggestions about mutated GPCRs. Our data also 31 raise a cautionary point about mutations: frequency of mutation of a gene is insufficient evidence to suggest its 32 importance as a potential oncogene or therapeutic target without additional analyses such as those noted above.
34
While we conclude that frequently mutated GPCRs are unlikely to be targets for therapeutic intervention in solid 
41
GPR98 locus in response to genome-wide damage appears to occur at a constant rate. This rate is elevated
42
relative to the rest of the coding genome in terms of mutation rate per kilobase. Understanding how and why this 43 occurs may provide additional insight into the mechanisms that drive DNA damage.
45
Known driver mutations do not appear to influence GPCR expression in tumors but we excluded rare mutations.
46
In order to ensure large numbers of replicates and high statistical significance, we analyzed tumors with high-
47
frequency mutations (e.g., P53 or KRAS) [9] . Highly expressed GPCRs are widely expressed among replicates of 
7
Given the widespread changes in copy number that occur in cancer, especially copy number amplification, which 8 might explain the increased expression of particular GPCRs in tumors, we tested but failed to find that CNV can 9 generally explain altered GPCR mRNA expression or DE. CNV is not stochastically distributed among the GPCR 10 family, certain GPCRs are more frequently amplified (e.g., GPR160) or deleted (e.g., PTH1R in KIRC). Amplified
11
and deleted GPCRs may have potential as biomarkers [47] . Our findings with respect to CNV and GPCRs raise a 12 broader concern and cautionary note: changes in copy number of certain genes should not be taken as evidence
13
of dysregulation of the same genes, unless one obtains evidence for corresponding changes at the mRNA level.
15
Numerous solid tumors have increased mRNA expression of large numbers of mostly non-mutated GPCRs: 72
16
GPCRs are overexpressed in >10 tumor subtypes, implying that common mechanisms may regulate GPCR 
21
The data reveal that clusters of GPCRs may be prognostic indicators for survival and provide a molecular 
27
Do GPCR mRNA data predict protein expression? Direct quantification of GPCR proteins is challenging, due to 28 their generally low abundance and paucity of well-validated antibodies. However, mRNA expression of GPCRs,
29
especially highly expressed GPCRs, generally predicts the presence of functionally active GPCRs in human and
30
animal cells [48] [49] [50] [51] [52] . In contrast to earlier ideas, recent evidence supports the view that mRNA expression
31
broadly predicts protein expression [53] [54] [55] [56] [57] (Supplemental Note 1). As an example, GPRC5a protein and mRNA
32
abundance are concordant (Supplemental Note 2; Fig S11) . GPCR detection via mass-spectrometry has been 33 challenging; proteomics data (e.g., [58] indicate that at present, few GPCRs are detectable by such methods,
34
likely due to the low abundance of GPCR proteins. As noted in Results, functional evidence is available for
35
numerous GPCRs with DE in solid tumors. As cell-surface proteins enriched in tumors and cancer cells, certain
36
GPCRs may represent novel tumor-associated proteins that might be targeted for diagnosis and/or treatment.
38
As a caveat to those ideas regarding mRNA and proteins expression, most analyses on their concordance cited 
45
and/or protein expression in a range of settings, including cancer, for GPCRs identified as highly expressed,
46
based on omics methods (reviewed in [50] ). We thus suggest that highly expressed GPCRs (e.g. those expressed at ≥ 5-10 TPM from RNA-seq data) are very likely to be functional.
49
GPCR mutations, CNV and DE thus occur at a high frequency in solid tumors. Therefore, this receptor super- 
5
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The analyzed data from the TOIL project were generated as follows. Merged FASTQ files were adapter-trimmed 10 via CUTADAPT, followed by alignment via STAR [60] . Gene expression was then quantified using RSEM [61] .
11
The HG38 reference genome, with Gencode V23 annotations, was used in the TOIL analysis. For this study, both
12
RSEM estimated counts (for DE analysis) and RSEM TPMs (for evaluating magnitudes of expression) were used.
14
Files were accessed from 
27
We used a 
36
Adenocarcinoma (Fig S1A-F) , hence requiring this subdivision into tumor subtypes.
38
In addition to the standard TMM approach in edgeR, we tested upper-quartile normalization before conducting DE 39 analysis in edgeR. The two methods yielded nearly identical results (Fig S11C, D) e.g., EDNRB, GPR143 and ADGRG1 in SKCM (Fig S2F-H 
19
For mutation data, we used results obtained via the Broad Automated Pipeline, where available. In other cases,
20
we used data from the Baylor College of Medicine sequencing center. The source of the mutation data is 21 indicated on the respective downloadable files and Table S1 . In all cases, the HG19 reference genome was used
22
for calling mutations. Mutation data for genes coding for GPCRs were extracted as part of the present study; all
23
GPCR mutation data are available for download as supplemental material.
25
TCGA copy number estimates were obtained using Affymetrix SNP 6.0 arrays. 46 47 GPCR expression in a range of cancer cell lines was queried via the EBI Expression Atlas pipeline, described in detail in [37] 
21
pipeline, discussed in section 2 above. We focused on genes with significant DE and high expression 22 because our primary goal was to identify GPCRs that may be drug targets and/or biomarkers.
24
For compilation and distribution of data we assembled data files primarily in Microsoft Excel, with files stored in
25
.xlsb format.
27
Plots of normalized expression in tumors and normal tissue, whether in TPM or CPM, show median expression
28
for respective cohorts, along with upper and lower quartiles, as indicated in figure legends where applicable.
30
The numbers of replicates in each sample group/category of normal tissue and tumors are provided in Tables S1   31   and S2 and Table 1 (Figures S1G-J) .
42
The overlap, however, is not exact. In several cases, we found differences between TCGA normal and GTEX
43
samples. It is unclear if these differences result from biological or technical factors; prior data show that tumors 44 impact surrounding "normal" tissue and can also induce global changes [65] [66] [67] [68] . Hence, we have not used batch-
45
correction methods to account for these variations between TCGA normal and GTEX tissues. In general, DE of
46
GPCRs is similar whether TCGA normal tissue or GTEX tissue is compared to TCGA tumor samples (e.g.,
Figures S11E-F) suggesting that such differences are unlikely to impact upon the general conclusions of this 48 study.
50
For TCGA data, some recent efforts (e.g. 
6
In light of this, we present all data from TCGA and GTEX without correcting for batch effects.
8
In nearly all cases, DE of GPCRs we highlight have large fold changes with high statistical significance (i.e., FDR
9
<< 0.05), such that minor technical variations ought not substantially impact our key findings. Moreover, the fact 10 that TCGA tumors and GTEX normal tissues form distinct, separated clusters (and hence show a high degree of 11 DE) is unlikely to be due to technical factors. In several cases (e.g., KICH matched normal vs GTEX kidney 12 samples; Fig S1G) , TCGA matched normal and GTEX normal tissues are in fact highly similar, whereas in other 13 cases they are not (e.g., PRAD, Fig S1J) . This suggests that technical factors between the two studies do not 14 consistently skew/bias the two data sets vs. each other.
16
Analysis to identify dependence of GPCR expression on patient characteristics, such as sex or tumor stage was 
28
to TP53 or KRAS) and association between GPCR mRNA expression and the thresholded GISTIC 2.0 CNV call.
30
Survival analysis was performed in R using gene expression data normalized in CPM (i.e., units appropriate for
31
comparisons between samples) via the "survival" and "survminer" packages. For each tumor type analyzed,
32
samples were divided into two groups based on median expression of the gene being tested, and differences in 33 survival between the two groups were calculated. The modified Peto-Peto (mPP) method was used to estimate 34 the statistical significance of differences in survival rates. We noted cases where the effects of GPCR expression 35 on survival were related/coupled (hence, the presence of composite markers of survival noted in the text). Thus,
36
these statistical tests were not independent; given a lack of understanding about the nature of such dependencies
37
(which to our knowledge were hitherto unknown), we did not adjust p-values for multiple testing. We also note 
42
of genes with survival that may differ in some cases from other sources that also provide survival analysis of
43
TCGA data. We selected a significance threshold of p < 0.05, which is relatively lenient for survival analysis, as 44 our initial priority was to minimize false negatives; we anticipate these analyses will need subsequent validation 45 efforts in specific tumor types, with larger numbers of patients. 
47
Data and Software Availability
